DeepMed Research

Abramson Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.pennmedicine.org

Clinical Trials

Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy

Terminated

Conditions: Non-Small Cell Lung Cancer (NSCLC)

First Posted Date: 2015-11-18

Last Posted Date: 2021-03-18

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 10

Registration Number: NCT02608528

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Pragmatic Randomized Trial of Proton Vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer: a Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial

Not Applicable

Active, not recruiting

Conditions: Breast Cancer

Interventions: Radiation: Proton
Radiation: Photon

First Posted Date: 2015-11-11

Last Posted Date: 2024-10-22

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 1238

Registration Number: NCT02603341

Locations: 🇺🇸
Abramson Cancer Center at Penn Medicine, Philadelphia, Pennsylvania, United States
🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸
Mayo Clinic-Arizona, Phoenix, Arizona, United States

and more 37 locations

A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer

Phase 1

Completed

Conditions: Advanced Breast Cancer

Interventions: Drug: Ribociclib (LEE011)
Drug: Paclitaxel

First Posted Date: 2015-11-06

Last Posted Date: 2023-11-09

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 18

Registration Number: NCT02599363

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma

Phase 1

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: RO70097890
Drug: nab-paclitaxel
Drug: gemcitabine

First Posted Date: 2015-10-27

Last Posted Date: 2022-09-06

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 19

Registration Number: NCT02588443

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Improving Clinical Trial Awareness in NSCLC: Pilot Testing A Novel Healthcare IT Platform for Incorporating Education at the Point of Care

Not Applicable

Completed

Conditions: Non-Small Cell Lung Carcinoma (NSCLC)

First Posted Date: 2015-09-24

Last Posted Date: 2020-02-06

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 120

Registration Number: NCT02558998

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Study on Breast Cancer Patient Perspectives of Exercise

Completed

Conditions: Breast Cancer

First Posted Date: 2015-09-24

Last Posted Date: 2020-04-09

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 26

Registration Number: NCT02559362

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

PAIN-LESS: Understanding and Alleviating Pain for Cancer Patients in Academic and Community Hospitals

Completed

Conditions: Cancer

First Posted Date: 2015-09-24

Last Posted Date: 2019-07-23

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 466

Registration Number: NCT02559375

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

LIVESTRONG Survivorship Care Plan: Continued Data Collection and Follow Up Survey

Completed

Conditions: Cancer Patient

First Posted Date: 2015-09-24

Last Posted Date: 2022-07-19

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 2000

Registration Number: NCT02559323

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

CTCs for High Grade Glioma

Completed

Conditions: Stage III and IV Glioma Patients

First Posted Date: 2015-09-24

Last Posted Date: 2020-04-24

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 30

Registration Number: NCT02558335

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Validation of Edema-invariant Multi-shell High Angular Resolution Diffusion Imaging (msHARDI)-Based Tractography With Intra-operative Cortical Stimulation

Completed

Conditions: Brain Lesions

First Posted Date: 2015-09-24

Last Posted Date: 2023-04-18

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 68

Registration Number: NCT02559401

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy